These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12395995)

  • 21. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin.
    Brin MF; Blitzer A; Stewart C
    Adv Neurol; 1998; 78():237-52. PubMed ID: 9750921
    [No Abstract]   [Full Text] [Related]  

  • 23. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Whurr R; Lorch M; Fontana H; Brookes G; Lees A; Marsden CD
    J Neurol Neurosurg Psychiatry; 1993 May; 56(5):526-30. PubMed ID: 8505645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin for spasmodic dysphonia.
    Rodriquez AA
    Phys Med Rehabil Clin N Am; 2003 Nov; 14(4):767-79. PubMed ID: 14580036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
    Stong BC; DelGaudio JM; Hapner ER; Johns MM
    Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Laryngeal dystonia. Comparison of transcutaneous and transoral injection of botulinum toxin].
    García Ruiz PJ; Cenjor Español C; Sánchez Pernaute R; Astarloa R; Sánchez Bernardos V; García de Yébenes Prous J
    Neurologia; 1996; 11(6):216-9. PubMed ID: 8768677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [First use of botulinum toxin type B in ENT patients with secondary therapy failure of botulinum toxin type A].
    Guntinas-Lichius O
    HNO; 2004 Jan; 52(1):53-6. PubMed ID: 14740116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of methods of botulinum toxin injection for abductory spasmodic dysphonia.
    Meleca RJ; Hogikyan ND; Bastian RW
    Otolaryngol Head Neck Surg; 1997 Nov; 117(5):487-92. PubMed ID: 9374172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of spasmodic dysphonia with botulinum toxin].
    Vilkman E; Laurikainen E; Marttila R
    Duodecim; 1995; 111(16):1546-51. PubMed ID: 9273263
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin.
    Park JB; Simpson LL; Anderson TD; Sataloff R
    J Voice; 2003 Jun; 17(2):255-64. PubMed ID: 12825657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia.
    Benninger MS; Gardner G; Grywalski C
    Arch Otolaryngol Head Neck Surg; 2001 Sep; 127(9):1083-5. PubMed ID: 11556856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.
    Jankovic J; Orman J
    Neurology; 1987 Apr; 37(4):616-23. PubMed ID: 3561773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
    Adler CH; Bansberg SF; Krein-Jones K; Hentz JG
    Mov Disord; 2004 Sep; 19(9):1075-9. PubMed ID: 15372600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharyngeal Dystonia Mimicking Spasmodic Dysphonia.
    Shi LL; Simpson CB; Hapner ER; Jinnah HA; Johns MM
    J Voice; 2018 Mar; 32(2):234-238. PubMed ID: 28651822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.
    Murry T; Woodson GE
    J Voice; 1995 Dec; 9(4):460-5. PubMed ID: 8574315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin treatment for spasmodic dysphonia.
    Kobayashi T; Niimi S; Kumada M; Kosaki H; Hirose H
    Acta Otolaryngol Suppl; 1993; 504():155-7. PubMed ID: 8470525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between clinical response and injection quality in treatment of spasmodic dysphonia.
    Tewary AK
    J Laryngol Otol; 1996 Jun; 110(6):551-3. PubMed ID: 8763375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient Experience Contributing to Outcomes of Laryngeal Botulinum Toxin Injection.
    Rutt A; Kennelly KD; Martinez-Paredes JF
    J Voice; 2022 Mar; 36(2):272-276. PubMed ID: 32553551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The treatment of laryngeal movement disorders with botulinum toxin: part 2: experience and considerations].
    Schwemmle C; Ptok M
    HNO; 2007 Jun; 55(6):485-8. PubMed ID: 17431566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of using botulism toxin in the treatment of spasmodic dysphonia].
    Larrosa F; Idígora A; Aguilar F; Riera L; Martí MJ; Valls J
    Acta Otorrinolaringol Esp; 2002 Jan; 53(1):27-31. PubMed ID: 11998515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.